Oncology Biosimilars Market Analysis by Drug Class (G-CSF, Monoclonal Antibody, Hematopoietic Agents), by Disease Indication (Breast Cancer, Colorectal Cancer, Neutropenia, Leukemia) by Distribution Channel, by Region - Global Insights 2022-2032
Report Highlights
Oncology Biosimilars Market- Scope of Report
A recent study by Fact.MR on the oncology biosimilars market offers a 10-year forecast for 2022 to 2032. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering oncology biosimilars.
The study also provides the dynamics responsible for influencing the future status of the oncology biosimilars market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.
A list of prominent companies operating in the oncology biosimilars market, along with their product portfolios, enhances the reliability of this comprehensive research study.
Report Summary
The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of oncology biosimilars across the globe.
A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of oncology biosimilars during the forecast period. Price point comparison by region with global average price is also considered in the study.
Analysis on Market Size Evaluation
The market has been analyzed for each segment in terms of volume (‘000 Units) and value (US$ Mn).
Estimates at global and regional levels for oncology biosimilars are available in terms of “US$ Mn” for value and in “‘000 Units” for volume. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report. Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global oncology biosimilars market.
Inspected Assessment on Regional Segments
Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the oncology biosimilars during the forecast period.
Country-specific valuation on demand for oncology biosimilars has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value & volume for emerging countries has also been included in the report.
In-depth Analysis on Competition
The report sheds light on leading manufacturers of oncology biosimilars, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering Oncology Biosimilars has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the oncology biosimilars domain.
- Table 1 : Global Biosimilars Market Snapshot
- Table 2 : Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
- Table 3 : Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032
- Table 4 : Global Oncology Biosimilars Market Size (US$ Mn) Forecast, Blood Cancer, 2022-2032
- Table 5 : Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032
- Table 6 : Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
- Table 7 : Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2022-2032
- Table 8 : Approved Oncology Biosimilars by USFDA in new biosimilars pathway established under BPCIA Act
- Table 9 : North America Oncology Biosimilars: Pipeline Overview, 2017-2020
- Table 10 : North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032
- Table 11 : North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
- Table 12 : Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032
- Table 13 : Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
- Table 14 : Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032
- Table 15 : Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2022-2032
- Table 16 : Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032
- Table 17 : Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
- Table 18 : Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032
- Table 19 : Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
- Table 20 : Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032
- Table 21 : Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2022-2032
- Table 22 : Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032
- Table 23 : Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
- Table 24 : Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032
- Table 25 : Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, Drug Class, 2022-2032
- Table 26 : Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032
- Table 27 : Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2022-2032
- Table 28 : Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032
- Table 29 : Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
- Figure 1 : Global Oncology Biosimilars Market Size (US$ Mn) Forecast, 2022-2032
- Figure 2 : Global Oncology Biosimilars Market Value Share, by Drug Class (2021)
- Figure 3 : Global Oncology Biosimilars Market Value Share, by Disease Indication (2021)
- Figure 4 : Global Oncology Biosimilars Market Value Share, by Distribution Channel (2021)
- Figure 5 : Global Oncology Biosimilars Market Value Share, by Region (2021)
- Figure 6 : U.S. Prevalence Share (%), By Cancer Type, 2015
- Figure 7 : Global Estimation of Cancer, By New Cases & Deaths, 2021
- Figure 8 : Global Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032
- Figure 9 : Global Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032
- Figure 10 : Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Monoclonal Antibody, 2022-2032
- Figure 11 : Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hematopoietic Agents, 2022-2032
- Figure 12 : Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by G-CSF, 2022-2032
- Figure 13 : Global Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032
- Figure 14 : Global Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032
- Figure 15 : Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Breast Cancer, 2022-2032
- Figure 16 : Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Non-small Cell Lung Cancer, 2022-2032
- Figure 17 : Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Blood Cancer, 2022-2032
- Figure 18 : Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Colorectal Cancer, 2022-2032
- Figure 19 : Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Neutropenia, 2022-2032
- Figure 20 : Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2022-2032
- Figure 21 : Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
- Figure 22 : Global Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
- Figure 23 : Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacy, 2022-2032
- Figure 24 : Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacy, 2022-2032
- Figure 25 : Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacy, 2022-2032
- Figure 26 : Global Oncology Biosimilars Market Value Share, by Region, 2022 and 2032
- Figure 27 : Global Oncology Biosimilars Market Attractiveness, by Region, 2022-2032
- Figure 28 : North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
- Figure 29 : North America Oncology Biosimilars Market Value Share, by Country, 2022 and 2032
- Figure 30 : North America Oncology Biosimilars Market Attractiveness, by Country, 2022-2032
- Figure 31 : North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
- Figure 32 : North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
- Figure 33 : Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
- Figure 34 : Europe Oncology Biosimilars Market Value Share, by Country, 2022 and 2032
- Figure 35 : Europe Oncology Biosimilars Market Attractiveness, by Country, 2022-2032
- Figure 36 : Europe Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032
- Figure 37 : Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032
- Figure 38 : Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032
- Figure 39 : Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032
- Figure 40 : Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
- Figure 41 : Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
- Figure 42 : Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2022-2032
- Figure 43 : Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2022 and 2032
- Figure 44 : Asia Pacific Oncology Biosimilars, Market Attractiveness, by Country, 2022-2032
- Figure 45 : Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032
- Figure 46 : Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032
- Figure 47 : Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032
- Figure 48 : Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032
- Figure 49 : Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
- Figure 50 : Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
- Figure 51 : Rest of the World Oncology Biosimilars, Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2022-2032
- Figure 52 : Rest of the World Oncology Biosimilars Market Value Share, by Country, 2022 and 2032
- Figure 53 : Rest of the World Oncology Biosimilars, Market Attractiveness, by Country, 2022-2032
- Figure 54 : Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032
- Figure 55 : Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032
- Figure 56 : Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032
- Figure 57 : Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032
- Figure 58 : Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
- Figure 59 : Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
- Figure 60 : Global Oncology Biosimilars Market Share, by Company, 2021
- Figure 61 : Breakdown of Net Sales of Sandoz International GmbH (A Novartis Division), by Franchise, 2021 (%)
- Figure 62 : Revenue (US$ Bn) & Y-o-Y Growth (%) of Sandoz International GmbH (A Novartis Division), 2015-2021
- Figure 63 : Breakdown of Net Sales of Pfizer, Inc., by Region, 2021 (%)
- Figure 64 : Revenue (US$ Bn) & Y-o-Y Growth (%) of Pfizer, Inc., 2015-2021
- Figure 65 : Breakdown of Net Sales of Celltrion Inc., by Business Segments, 2021
- Figure 66 : Revenue (US$ Mn) & Y-o-Y Growth (%) of Celltrion Inc., 2015-2021
- Figure 67 : Breakdown of Net Sales of Dr. Reddy’s Laboratories Ltd., by Business Segments, 2021 (%)
- Figure 68 : Revenue (US$ Bn) & Y-o-Y Growth (%) of Dr. Reddy’s Laboratories Ltd., 2015-2021
- Figure 69 : Breakdown of Net Sales of Biocon, by Business Segments, 2021 (%)
- Figure 70 : Revenue (US$ Mn) & Y-o-Y Growth (%) of Biocon, 2015-2021
- Figure 71 : Breakdown of Net Sales of Teva Pharmaceutical Industries Ltd., by Business Segments, 2021 (%)
- Figure 72 : Revenue (US$ Bn) & Y-o-Y Growth (%) of Teva Pharmaceutical Industries Ltd., 2015-2021
- Figure 73 : Breakdown of Net Sales of STADA Arzneimittel AG, by Business Segments, 2021 (%)
- Figure 74 : Revenue (US$ Bn) & Y-o-Y Growth (%) of STADA Arzneimittel AG, 2015-2021
- Figure 75 : Revenue (US$ Mn) & Y-o-Y Growth (%) of Intas Pharmaceuticals Ltd., 2015-2021
Fact.MR is an independent, pure play market intelligence firm incorporated with an objective to deliver high quality, customized market research solutions that help our clients successfully go to the market equipped with actionable insights capable of impacting crucial business decisions.
Similar Reports from Fact Market Research
Oncology Biosimilars Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025
Global Oncology Biosimilars Market- Scope of the Report
The recent study by Fact.MR on the global oncology biosimilars market offers a 5-year forecast between 2020 and 2025. The study analyzes crucial trends currently determining the growth of the market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders ...